Assess whether to drop a secondary endpoint that will dominate the AdCom

SITUATION CMC and Development Pathways work in a mid-size sponsor after a complete response letter now turns on to drop a secondary because an AdCom briefing document that overstates subgroup findings put inspection-readiness findings at a CMO in play. CMC and Development Pathways work in a mid-size sponsor after a complete response letter now turns on to drop a secondary because an AdCom briefing document that overstates subgroup findings put inspection-readiness findings at a CMO in play; pharmacovigilance medical reviewer should say what inspection-readiness findings at a CMO proves for Pharma & Life Sciences.

DECISION Pharmacovigilance medical reviewer in a mid-size sponsor after a complete response letter must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using inspection-readiness findings at a CMO after an AdCom briefing document that overstates subgroup findings.

HYPOTHESES TO TEST 1. Pharmacovigilance medical reviewer can defend Proceed under protocol from inspection-readiness findings at a CMO after an AdCom briefing document that overstates subgroup findings in a Pharma & Life Sciences challenge. 2. Pharmacovigilance medical reviewer cannot defend Proceed under protocol from inspection-readiness findings at a CMO; Pause the pathway is what the extract actually supports after an AdCom briefing document that overstates subgroup findings. 3. An AdCom briefing document that overstates subgroup findings never reached the population in inspection-readiness findings at a CMO — reopen intake, do not close to drop a secondary. 4. Two facts in inspection-readiness findings at a CMO after an AdCom briefing document that overstates subgroup findings conflict for pharmacovigilance medical reviewer; hold this CMC and Development Pathways file.

ANALYSIS REQUIRED 1. Trace CMC, labeling, or pharmacovigilance facts in inspection-readiness findings at a CMO after an AdCom briefing document that overstates subgroup findings. 2. Separate an isolated adverse event from a systemic quality issue. 3. Test a protocol deviation versus a safety signal versus a filing gap on to drop a secondary. 4. For this Pharma & Life Sciences CMC and Development Pathways file, read inspection-readiness findings at a CMO against an AdCom briefing document that overstates subgroup findings and write the one fact that would move to drop a secondary for pharmacovigilance medical reviewer.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / CMC and Development Pathways packet (inspection-readiness findings at a CMO after an AdCom briefing document that overstates subgroup findings). The follow-on CMC and Development Pathways action is what pharmacovigilance medical reviewer does next: implement the option, assign an owner, and log the missing fact.